Prospectus and Rights Issues

January 9, 2025

SynAct Pharma AB resolves on a directed share issue to guarantors

January 9, 2025

SynAct Pharma AB announces outcome of the rights issue

November 20, 2024

Rights Issue December 2024

March 26, 2024

Directed Share Issue 2024

October 12, 2023

Directed rights issue 2023

July 8, 2022

Listing on Nasdaq 2022

March 28, 2022

Rights Issue 2022

June 30, 2020

Series TO 2 subscription options

October 21, 2019

Rights issue 2019

March 9, 2017

Series TO 1 subscription options

June 3, 2016

Publication of additional prospectus

May 24, 2016

Publication of SynAct Pharma AB’s prospectus in connection with the issue ahead of planned listing on Aktietorget